SAN DIEGO, May 3, 2012 /PRNewswire/ -- Profil® Institute for Clinical Research, Inc., a company focused on early phase clinical trials for diabetes and obesity, announced today record growth in the number of clinical trials in the pipeline. Profil Institute also reports an increase in the number of mid-size biotech and off-shore clients, while maintaining active collaborations with the largest global pharmaceutical companies, driven by a strong demand for Phase I and metabolic disease specialization.
Profil Institute's advances in early phase drug research and its specific focus on diabetes, obesity and cardiometabolic diseases as it relates to the diabetic patient population have led Profil Institute to be recognized in the pharmaceutical community as the most highly regarded clinical research institute for early phase diabetes drug trials.
"Pharmaceutical clients are facing increased pressure to be more selective and efficient with their drug candidate trials and as such are turning to specialized institutes like Profil Institute to run more complex and meaningful studies," said Profil Institute CEO Dr. Marcus Hompesch. "While other CROs are responding to this trend, specialization has been Profil Institute's strategy since the company's inception and our business has grown as a result. We now have a record number of projects in our pipeline, active collaborations with the largest global pharmaceutical companies, and a rapidly growing number of mid-size pharmaceutical and biotech clients."
Although considered a CRO (Clinical Research Organization), the founders of Profil Institute have never considered their company to accurately fit that description. Instead they coined the term CRI, Clinical Research Institute, and define it as"uniting independent academic science with the professionalism of the pharmaceutical industry" – combining distinct academic intellect with the means to effectively design and execute clinical trials for their biopharmaceutical clients. In essence, Profil Institute's "deeper value" CRI approach is based on assisting their clients in the design and execution of the most meaningful early phase clinical studies, thereby generating relevant high quality data and accelerating the drug and device development process.
In Profil Institute's case, "specialized," can be added in front of the term CRI because of their disease focus on diabetes, obesity and cardiometabolic diseases. This concept of a specialized clinical research institute gives Profil Institute a substantial advantage in the industry by enabling Profil Institute to outperform peers in meaningful study design, study execution and study data interpretation.
About Profil® Institute for Clinical Research, Inc.
Profil Institute is world-renowned as a Center of Excellence for diabetes and obesity early phase clinical research. The company's advances in early phase drug research and its specific focus on diabetes, obesity and cardiometabolic diseases as it relates to the diabetic patient population have led Profil Institute to be the most highly regarded clinical research institute for early phase diabetes drug trials.
To date, Profil Institute has been involved with every clinically promising drug category and device development in diabetes and in more than 175 clinical studies since the company's inception in 2004. Contributing to Profil Institute's success is that the company is recognized as the leader in automated glucose clamps, considered the "Gold Standard" for the evaluation of anti-diabetic drugs and devices. The company's key scientists hail from academic centers including the WHO Collaborating Center of Diabetes at the Heinrich-Heine University of Dusseldorf, Columbia University, University of Michigan and Harvard University. For more information visit www.profilinstitute.com.
|SOURCE Profil Institute for Clinical Research, Inc.|
Copyright©2010 PR Newswire.
All rights reserved